As far as we are aware, this present clinical case is the first to report an acquired exon14 MET mutation
mediated resistance to alectinib in a patient with ALK rearrangement NSCLC. We had chosen to treat
our patient at the time of progression under alectinib with crizotinib with a short time efficacy, three and a
half months. READ ARTICLE
JTO Clinical and Research Reports DOI:10.1016/j.jtocrr.2020.100082
Authors: Catherine Daniel, Celine Callens, Samia Melaabi, Ivan Bieche, Nicolas Girard,